US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Oxcia will present at the BioStock Life Science Summit, November 20

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Ulrika Warpman Berglund will present Oxcia to specialist life science investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: November 20 Time: 11:05 Location: Auditorium at Medicon Village, Lund Read

Oxcia is focusing the development of OXC-101 on hematological cancers

Following a strategy and data review, Oxcia has chosen to re-prioritize the clinical development of OXC-101 from solid tumors to hematological cancers, specifically acute myeloid leukemia (AML). The preclinical program for OXC-101 has shown good results in both AML and other forms of hematological cancers, and data to date from the phase I/II study MAATEO confirm the previous results. Oxcia has initiated an expansion part of the MAATEO study in patients with refractory/relapsed AML (R/R AML), where OXC-101 is administered in combination with idarubicin (an anthracycline). - The first AML

New publications in peer-reviewed scientific journals support the potential for OXC-101 as a novel anti-cancer therapy

OXC-101 shows promise in enhancing the effectiveness of immune checkpoint inhibitors. The article published in Oncogenesis by Helleday laboratory, Karolinska Institute, and Oxcia team suggests that the mitotic MTH1 inhibitor OXC-101 (TH1579) has the potential to enhance the effectiveness of immune checkpoint inhibitors (ICI) in cancer treatment. This is achieved by influencing immune checkpoint-related proteins and pathways (1). The researchers discovered that treatment with OXC-101 leads to an increase in PD-L1 expression and inflammatory response in cancer cell lines. This finding may

Patent approval now also secured in the US, the largest IPF market

Following the recent patent application approvals in Japan and China, the patent (composition of matter) for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in the largest market, the US. The US represents 57% of the prevalence and incidence of IPF in the 7 major markets and as much as 82% of the market value. The patent is valid at least until 2040. Additional national and regional patent applications are pending in Europe (EPO - European Patent Organization) and Canada. As previously communicated,

Another key milestone for OXC-201 – patent approval in China

Following the recent patent application approval in Japan, the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in China. China and Asia in general are major markets for OXC-201. Asia is estimated to have the largest number of cases of pulmonary fibrosis in the world. Additional national and regional patent applications are pending in the US, Europe (EPO - European Patent Organization) and Canada. As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early

Oxcia AB Publishes Year-End Report for 2023

Fourth quarter (October-December 2023) · Operating loss totaled SEK -5,741,054 (-8,972,042). · Loss for the period totaled SEK -5,393,601 (-8,912,366). · Cash flow from operating activities totaled SEK -5,064,247 (-9,565,926). · Earnings per share before dilution totaled SEK -0.23 (-0.41). · Earnings per share after dilution amounted to SEK -0.23 (-0.41). · Proposed dividend of SEK 0.00 per share (0.00). Period (January-December 2023) · Operating loss totaled SEK -33,658,614 (-32,280,497). · Loss for the period totaled SEK -32,608,036 (-32,220,821). · Cash

Oxcia AB presents positive effects of OXC-201 in lung tissue from patient with Idiopatic Pulmonary Fibrosis

Oxcia presents new preclinical data on OXC-201 at the 7th IPF summit in Boston, September 19-21 and European Respiratory Society (ERS) International Congress 2023 September 9–13.  Lung tissue from IPF patients express high levels of several fibrotic biomarkers. Treatment with clinically relevant doses of OXC-201 demonstrated robust dose-dependent reduction of a number of the most important fibrosis-related biomarkers such as TGF-ß and collagen. These data correlate well with results from previous preclinical models, supporting OXC-201 as a potential treatment for IPF.   Christina

Oxcia AB (publ) publishes interim report for the second quarter 2023

Oxcia AB (publ) Interim report 1 January- 30 June 2023   Second quarter (April-June 2023) · Operating loss totaled SEK -6 937 299 (-7 068 278) · Loss for the period totaled SEK -6 600 725 (-7 068 278) · Cash flow from operating activities totaled SEK 395 205 (-5 963 346) · Earnings per share before dilution totaled SEK -0,31 (-0,33) · Earnings per share after dilution amounted to SEK -0,31 (-0,33) Period (January-June 2023) · Operating loss totaled SEK -23 503 674 (-12 381 412) · Loss for the period totaled SEK -23 051 192 (-12 381 412) · Cash flow

OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovery Science & Technology, Amsterdam 12-14 July, 2023

Oxcia’s CEO Ulrika Warpman Berglund has been invited to present “OXC-101: A Novel Way to Treat Acute Myeloid Leukemia by Inducing Mitotic Arrest, ROS and Oxidative Damage” at the 18[th] Annual Congress of International Drug Discovery Science & Technology (IDDST) conference, Amsterdam, the Netherlands, July 12-14, 2023. OXC-101 is a mitotic MTH1 inhibitor, with a unique synergistic dual mechanism of action. It arrests cancer cells in mitosis by disturbing microtubule polymerization, thereby accumulating ROS which in turn generates e.g. oxidized nucleotides. By inhibiting the enzyme MTH1,

Oxcia AB (publ) publishes interim report fort the first quarter 2023

First quarter (January-March 2023) Operating loss totaled SEK -16,566,375 (-5 313 134). Loss for the period totaled SEK – 16,450,467 (-5 313 134). Cash flow from operating activities totaled SEK – 6,760,934 (-4 993 784). Earnings per share before dilution totaled SEK -0,76 (-0.25). Earnings per share after dilution amounted to SEK -0.76 (-0.25).    Significant events in the first quarter •       Thomas Helleday’s Foundation for Medical Research receives approved patent BR112015011497, which includes OXC-101, in Brazil. Oxcia has a lifetime, exclusive license to the

Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients

In tough competition in Swelife’s and Medtech4Health’s joint call for Collaborative projects for better health in 2022, Oxcia AB has been awarded a grant of 3 million SEK. The call aims to finance the development of innovative and sustainable life science solutions that contribute to strengthening Swedish competitiveness and increase patient benefit. The financed projects must have great potential to make care more efficient and contribute to sustainable growth. Oxcia is currently investigating OXC-101 in a phase 1 study in AML, MAATEO.  It is an oral drug. Preliminary data is promising

Three abstracts on OXC-101 selected for poster presentations at AACR 2023

Oxcia AB (publ) today reports that three abstracts on OXC-101, its clinical candidate for cancer, have been selected for poster presentations at the American Association for Cancer Research (AACRS) Annual meeting held in Orlando, Florida,  14-19[th] April, 2023 . The abstracts concern the clinical safety, further understanding of the broad anti-cancer efficacy and the mechanism of action and will be published in the online Proceedings supplement of the AACR journal Cancer Research.Many cancers suffer from oxidative stress and high levels of endogenous oxidative DNA damage. The enzyme MTH1

New pre-clinical study shows that OXC-201 may be a promising treatment for IPF (pulmonary fibrosis)

A new study, "Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model" (freely translated: Pharmacological OGG1 inhibition reduces acute lung injury and lung fibrosis in mice), was published on January 26 in Nature Communications ( https://doi.org/10.1038/s41467-023-36314-5, L. Tanner, A. B. Single, R. K. V. Bhongir , M. Heusel , T. Mohanty, C. A. Q. Karlsson, L. Pan, C-M. Clausson, J. Bergwik , K. Wang, C. K. Andersson, R. M. Oommen, J. S. Erjefält, J. Malmström, O. Wallner, I. Boldogh, T. Helleday, C. Kalderén & A. Egesten)

The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.

Oxcia is very pleased to announce that the EIC (the European Innovation Council) has selected Oxcia’s OXC-201 to receive an EIC Transition grant of 2.5 million Euros. The EIC is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and innovations. Oxcia is the only Swedish company to receive the grant in this call. OXC-201 has the potential to be a ground-breaking novel approach for treatment of IPF (Idiopathic Pulmonary Fibrosis), with potential to substantially improve and even halt inflammation and fibrosis. The project is based on novel

Data show OXC-201 may be a promising treatment for allergic asthma.

A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.Allergic asthma is a complex inflammatory disease characterized by wheezing, dyspnea, coughing, chest tightness and variable airflow

Enrolment completed and recommended phase II dose reached for OXC-101

Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase II dose has now been determined.  Study results will be reported the coming months.   “Completing enrolment in the MASTIFF study and determining the Phase 2 Recommended Dose are very significant milestone for our company and allows us to finalize planning of our phase II study” said Austin Smith, M.D, Chief Medical Officer, Oxcia. “We

Oxcia AB is strengthening the organization further

Several exciting pre-clinical and clinical studies are imminent. We are therefore happy that we have been able to recruit two very experienced and competent Scientists. Dr William Stafford has taken up the position as Translational Director from 1st of September. He will reinforce the Oxcia team with his background in oncology and redox biology, drug discovery and business development.  In addition, Sandra Ekstedt has joined Oxcia as Senior Scientist and will primarily support the work with OXC-201, Oxcias promising project for Idiopathic pulmonary fibrosis (IPF). She adds special expertise

New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)

According to a new study published online 28 Feb 2022 (Centio et al., "Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML", Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-21-0185. Online ahead of print), OXC-101 (TH1579, karonudib) can inhibit AML progression as monotherapy but also boost standard chemotherapy response in AML pre-clinical models. AML is an aggressive blood cancer with estimated 25% 5-year survival, mainly due to primary resistance or relapse towards standard therapeutic regimens.

Oxcia reports positive interim data from clinical phase I study in advanced solid cancers

Oxcia reports positive interim data from the first part of the MASTIFF study, a phase 1 dose- escalation study with OXC-101 in patients with advanced solid cancers. Oxcia is a pioneer in oxidative DNA damage and DNA Damage Response (the body's processes for repairing the damage that occurs to DNA) with a focus on developing new safe treatments for cancer or inflammation. OXC-101 has a unique mechanism of action that fights cancer by utilizing the cancer's inherently high levels of oxidative DNA damage and oxidative stress. OXC-101 induces cancer-specific oxidative stress and oxidative

Oxcia contracts Patheon for manufacturing and further strengthens the organization

Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase 2 clinical trials. OXC-101 is Oxcia's first-in-class anticancer drug candidate, currently in phase 1 studies in patients with advanced solid cancers or blood cancers.   Patheon is part of the global ThermoFisher Scientific Group and is a leading contract manufacturer with production in several countries.   Oxcia continues to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe